Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NEOGENOMICS, INC.

(NEO)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
8.610 USD   -0.58%
09/14Transcript : NeoGenomics, Inc. - Special Call
CI
08/29North American Morning Briefing: Powell's -2-
DJ
08/26Benchmark Downgrades NeoGenomics to Hold From Buy
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
8.87(c) 8.34(c) 8.92(c) 8.66(c) 8.61(c) Last
1 395 331 935 573 1 124 153 836 537 965 298 Volume
-0.78% -5.98% +6.95% -2.91% -0.58% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 491 M - -
Net income 2022 -165 M - -
Net Debt 2022 367 M - -
P/E ratio 2022 -6,49x
Yield 2022 -
Sales 2023 535 M - -
Net income 2023 -137 M - -
Net Debt 2023 408 M - -
P/E ratio 2023 -7,93x
Yield 2023 -
Capitalization 1 083 M 1 083 M -
EV / Sales 2022 2,95x
EV / Sales 2023 2,79x
Nbr of Employees 2 000
Free-Float 96,7%
More Financials
Company
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers,... 
More about the company
Ratings of NeoGenomics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about NEOGENOMICS, INC.
09/14Transcript : NeoGenomics, Inc. - Special Call
CI
08/29North American Morning Briefing: Powell's -2-
DJ
08/26Benchmark Downgrades NeoGenomics to Hold From Buy
MT
08/22NeoGenomics Shares Plunge After Needham Downgrade
MT
08/22Needham Downgrades NeoGenomics to Hold From Buy, Removes $16 Price Target, Expects 2023..
MT
08/18Piper Sandler Adjusts Price Target on NeoGenomics to $19 From $13, Reiterates Overweigh..
MT
08/16Neogenomics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PU
08/12Neogenomics Inc : Change in Directors or Principal Officers (form 8-K)
AQ
08/10BTIG Downgrades NeoGenomics to Neutral From Buy
MT
08/10Transcript : NeoGenomics, Inc. - Special Call
CI
08/10Goldman Sachs Adjusts Price Target on NeoGenomics to $20 From $18, Maintains Buy Rating
MT
08/09Needham Lowers Price Target for NeoGenomics to $16 From $19, Maintains Buy Rating
MT
08/09NeoGenomics Q2 Adjusted Loss Expands While Revenue Rises
MT
08/09Neogenomics : Reports Revenue of $125 Million in the Second Quarter - Form 8-K
PU
08/09Neogenomics, Inc. Provides Earnings Guidance for the Year 2022
CI
More news
News in other languages on NEOGENOMICS, INC.
08/22Les actions de NeoGenomics plongent après la rétrogradation de Needham
08/09La perte ajustée de NeoGenomics au 2e trimestre s'accroît alors que les revenus augment..
08/09Neogenomics, Inc. fournit des prévisions de bénéfices pour l'année 2022
08/09NeoGenomics, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos ..
08/09Earnings Flash (NEO) NEOGENOMICS annonce un chiffre d'affaires de 125,1 millions de dol..
More news
Analyst Recommendations on NEOGENOMICS, INC.
More recommendations
ETFs positioned on NEOGENOMICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Invesco S&P SmallCap Health Care ETF - USD1.1%1.24%United_States
HAN-GINS Indxx Healthcare Megatrend Equal W...0.97%5.80%-NC
Xtrackers MSCI Genomic Healthcare Innovatio...0.23%3.53%-NC
Invesco S&P SmallCap 600® Equal Weight ETF - USD0.21%-1.92%United_States
IShares S&P Small-Cap 600 Growth ETF - USD0.16%-0.83%United_States
More ETFs positioned on NEOGENOMICS, INC.
Chart NEOGENOMICS, INC.
Duration : Period :
NeoGenomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEOGENOMICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 8,61 $
Average target price 18,00 $
Spread / Average Target 109%
EPS Revisions
Managers and Directors
Christopher Michael Smith Chief Executive Officer
William Bishop Bonello Chief Financial Officer
Lynn A. Tetrault Independent Chairman
Steven A. Ross Chief Information Officer & Vice President
Forrest J. Holmes Blocker Director-Scientific Affairs
Sector and Competitors